PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF GLAUCOMA COMPRISING AN INHIBITOR OF SERINE-THREONINE KINASE, TYROSINE KINASE OR PROTEIN TYROSINE PHOSPHATASE OR AN ACTIN-DISRUPTING COMPOUND

摘要

Methods for the treatment of glaucoma are described. The compounds described cause a perturbation of cell adhesions in the trabecular meshwork, mainly via disruption of the associated cytoskeletal structures or the modulation of their interactions with the underlying membrane. Perturbation of these adhesions reduces the resistance of the trabecular meshwork to fluid flow and thereby reduces intraocular pressure.